Literature DB >> 33781510

Glioblastoma: Molecular Mechanisms and Clinical Trials.

Linda M Liau1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33781510     DOI: 10.1016/j.nec.2021.03.001

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


× No keyword cloud information.
  1 in total

1.  The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway.

Authors:  Ming Ji; Zhihui Zhang; Songwen Lin; Chunyang Wang; Jing Jin; Nina Xue; Heng Xu; Xiaoguang Chen
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.